Functional inhibitors of acid sphingomyelinase (FIASMAs)

Handbook of Experimental Pharmacology

Volumn 215, Issue , 2013, Pages 169-186

  Kornhuber, Johannes ^a   Tripal, Philipp ^a   Gulbins, Erich ^b   Muehlbacher, Markus ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Acid sphingomyelinase; Ceramide; Functional inhibitors; Structure Property Activity relation

Indexed keywords

ALVERINE; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; ANTIPRURITIC AGENT; APPETITE STIMULANT; APRINDINE; ASTEMIZOLE; BENZATROPINE; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; CERAMIDE; CISPLATIN; CLOFAZIMINE; CONNESINE; DICYCLOVERINE; ENZYME INHIBITOR; FLUOXETINE; FUNCTIONAL INHIBITOR OF ACID SPHINGOMYELINASE; GASTROINTESTINAL AGENT; MIBEFRADIL; SERTRALINE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRESS; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG USE; HUMAN; INTRACELLULAR SIGNALING; LIPID METABOLISM; MEMBRANE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; DRUG ANTAGONISM; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; ENZYME INHIBITORS; HUMANS; SPHINGOMYELIN PHOSPHODIESTERASE;

MLCS; MLOWN;

EID: 84880416491     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1368-4_9     Document Type: Article

References (66)

1. Abbott NJ, Romero IA (1996) Transporting therapeutics across the blood-brain barrier. Mol Med Today 2(3):106-113
2. Arenz C (2010) Small molecule inhibitors of acid sphingomyelinase. Cell Physiol Biochem 26(1): 1-8
3. Baker DE (2007) Loperamide: a pharmacological review. Rev Gastroenterol Disord 7(suppl 3): S11-S18
4. Becker KA, Riethmu? ller J, Lu?th A, Do?ring G, Kleuser B, Gulbins E (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42(6):716-724
5. Bikman BT, Summers SA (2011) Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 121(11):4222-4230
6. Black WC, Percival MD (2006) The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. ChemBioChem 7(10):1525-1535
7. Bollinger CR, Teichgra?ber V, Gulbins E (2005) Ceramide-enriched membrane domains Biochim Biophys Acta 1746(3):284-294
8. Bradbury MWB (1993) The blood-brain barrier. Exp Physiol 78(4):453-472
9. Brady RO, Kanfer JN, Mock MB, Fredrickson DS (1966) The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. Proc Natl Acad Sci 55(2): 366-369
10. Charruyer A, Grazide S, Bezombes C, Müller S, Laurent G, Jaffre'zou J-P (2005) UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J Biol Chem 280(19):19196-19204
11. Clark DE (2011) What has polar surface area ever done for drug discovery? Future Med Chem 3: 469-484
12. Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Lösche W, Kinscherf R, Deigner H-P (2005) Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J 19(12):1719-1721
13. Cuzzocrea S, Deigner H-P, Genovese T, Mazzon E, Esposito E, Crisafulli C, Di Paola R, Bramanti P, Matuschak G, Salvemini D (2009) Inhibition of ceramide biosynthesis ameliorates pathological consequences of spinal cord injury. Shock 31(6):635-645
14. de Boer AG, van der Sandt ICJ, Gaillard PJ (2003) The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 43:629-656
15. De Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F (1974) Lysosomotropic agents. Biochem Pharmacol 23(18):2495-2531
16. de Lange ECM (2004) Potential role of ABC transporters as a detoxification system at the blood- CSF barrier. Adv Drug Deliv Rev 56(12):1793-1809
17. Fe'art C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues J-F, Scarmeas N, Barberger-Gateau P (2009) Adherence to a mediterranean diet, cognitive decline, and risk of dementia. JAMA 302(6):638-648
18. Ferna'ndez A, Colell A, Garcia-Ruiz C, Fernandez-Checa JC (2008) Cholesterol and sphingolipids in alcohol-induced liver injury. J Gastroenterol Hepatol 23:S9-S15
19. Fischer H, Kansy M, Avdeef A, Senner F (2007) Permeation of permanently positive charged molecules through artificial membranes-influence of physico-chemical properties. Eur J Pharm Sci 31(1):32-42
20. Gallala HD, Sandhoff K (2011) Biological function of the cellular lipid BMP-BMP as a key activator for cholesterol sorting and membrane digestion. Neurochem Res 36(9):1594-1600
21. Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schu?tze S, Gulbins E, Uhlig S (2004) PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 10(2):155-160
22. Gracia-Garcia P, Rao V, Haughey NJ, Ratnam Banduru VV, Smith G, Rosenberg PB, Lobo A, Lyketsos CG, Mielke MM(2011) Elevated plasma ceramides in depression. J Neuropsychiatry Clin Neurosci 23(2):215-218
23. Grassmé H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E (2001) CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 276(23):20589-20596
24. Grassmé H, Jendrossek V, Riehle A, von Ku?rthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E (2003) Host defense against pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 9(3):322-330
25. Guidelines for ATC classifications and DDD assignment (2011) World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/filearchive/publications/2010guidelines.pdf. Accessed 19 Oct 2009
26. Han X, Holtzman DM, McKeel DW, Kelley J, Morris JC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82(4):809-818
27. He X, Huang Y, Li B, Gong C-X, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31(3):398-408
28. Hurwitz R, Ferlinz K, Sandhoff K (1994) The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 375(7):447-450 Inc. ACD ACD/PhysChem. version 10.0 edn., Toronto, ON, Canada. http://www.acdlabs.com
29. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA (1993) Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 5(3):322-329
30. Kaufmann AM, Krise JP (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96(4):729-746
31. Kim M-Y, Linardic C, Obeid L, Hannun Y (1991) Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem 266(1):484-489
32. Kolter T, Sandhoff K (2005) Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol 21(1):81-103
33. Kölzer M, Werth N, Sandhoff K (2004) Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett 559(1-3):96-98
34. Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, Gulbins E (2005) High activity of acid sphingomyelinase in major depression. J Neural Transm 112(11):1583-1590
35. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiftfang J, Gulbins E (2008) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 51(2):219-237
36. Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E (2010) Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 26(1):9-20
37. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E, Tripal P (2011) Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One 6(8):e23852
38. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Ru?bben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Ha?ussinger D, Gulbins E, Lang F (2007) Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 13(2):164-170
39. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1-3):3-26
40. Macauley SL, Sidman RL, Schuchman EH, Taksir T, Stewart GR (2008) Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration. Exp Neurol 214(2):181-192
41. Malaplate-Armand C, Florent-Be'chard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger- Muller B, Olivier J-L, Oster T, Pillot T (2006) Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 23(1):178-189
42. Mikati MA, Zeinieh M, Habib RA, El Hokayem J, Rahmeh A, El Sabban M, Usta J, Dbaibo G (2008) Changes in sphingomyelinases, ceramide, bax, bcl2, and caspase-3 during and after experimental status epilepticus. Epilepsy Res 81(2):161-166
43. Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31(6):246-254
44. Mintzer RJ, Appell KC, Cole A, Johns A, Pagila R, Polokoff MA, Tabas I, Snider RM, Meurer- Ogden JA (2005) A novel high-throughput screening format to identify inhibitors of secreted acid sphingomyelinase. J Biomol Screen 10(3):225-234
45. Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J (2008) Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 79(9): 1027-1031
46. Muehlbacher M, Tripal P, Roas F, Kornhuber J (2012) Identification of drugs inducing phospholipidosis by novel in vitro data. ChemMedChem 7(11):1925-1934
47. NdengeleMM, Cuzzocrea S, Masini E, VinciMC, Esposito E, Muscoli C, Petrusca DN, Mollace V, Mazzon E, Li D, Petrache I, Matuschak GM, Salvemini D (2009) Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther 329(1):64-75
48. Novelli A, Lysko PG, Henneberry RC (1987) Uptake of imipramine in neurons cultured from rat cerebellum. Brain Res 411(2):291-297
49. Nussio MR, Sykes MJ, Miners JO, Shapter JG (2007) Characterisation of the binding of cationic amphiphilic drugs to phospholipid bilayers using surface plasmon resonance. ChemMedChem 2(3):366-373
50. Pariente J, Loubinoux I, Carel C, Albucher J-F, Leger A, Manelfe C, Rascol O, Chollet F (2001) Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 50(6):718-729
51. Purvis GD (2008) Size-intensive descriptors. J Comput Aided Mol Des 22(6):461-468
52. Rebillard A, Rioux-Leclercq N, Muller C, Bellaud P, Jouan F, Meurette O, Jouan E, Vernhet L, Le Quement C, Carpinteiro A, Schenck M, Lagadic-Gossmann D, Gulbins E, Dimanche-Boitrel MT (2008) Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage. Oncogene 27(51):6590-6595
53. Reichel M, Greiner E, Richter-Schmidinger T, Yedibela Ö, Tripal P, Jacobi A, Bleich S, Gulbins E, Kornhuber J (2010) Increased acid sphingomyelinase activity in peripheral blood cells of acutely intoxicated patients with alcohol dependence. Alcohol Clin Exp Res 34(1):46-50
54. Reichel M, Beck J, Mu?hle C, Rotter A, Bleich S, Gulbins E, Kornhuber J (2011) Activity of secretory sphingomyelinase is increased in plasma of alcohol-dependent patients. Alcohol Clin Exp Res 35(10):1852-1859
55. Riethmü ller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 24 (1-2):65-72
56. Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, Toda A, Eyanagi R, Soeda S (2007) Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology 122(1):56-64
57. Santana P, Peña LA, Haimovitz-Friedman A, Martin S, Green D, McLou ghlin M, Cordon- Cardo C, Schuchman EH, Fuks Z, Kolesnick R (1996) Acid sphingomyelinase deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86(2):189-199
58. Schuchman EH (2007) The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis 30(5):654-663
59. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S (2008) High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7(10):4266-4277
60. Seto M, Whitlow M, McCarrick MA, Srinivasan S, Zhu Y, Pagila R, Mintzer R, Light D, Johns A, Meurer-Ogden JA (2004) A model of the acid sphingomyelinase phosphoesterase domainbased on its remote structural homolog purple acid phosphatase. Protein Sci 13(12):3172-3186
61. Short B (2010) Acid sphingomyelinase deals the seal. J Cell Biol 189(6):920
62. Smith EL, Schuchman EH (2008) The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J 22(10):3419-3431
63. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tu?mmler B, Lang F, Grassme H, Döring G, Gulbins E (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14(4):382-391
64. Trapp S, Rosania GR, Horobin RW, Kornhuber J (2008) Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J 37(8):1317-1328
65. Wiegmann K, Schütze S, Machleidt T, Witte D, KrönkeM(1994) Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78(6):1005-1015
66. Wilkening G, Linke T, Sandhoff K (1998) Lysosomal degradation on vesicular membrane surfaces. J Biol Chem 273(46):30271-30278